| Description | Cixutumumab (IMC-A12), a humanized monoclonal antibody targeting IGF-1R, exhibits high affinity and inhibits ligand-dependent receptor activation, impeding downstream signaling. Additionally, it facilitates the internalization and degradation of IGF-1R. Demonstrating extensive antitumor efficacy, it is relevant in cancer research, including lung and prostate cancers, malignancies, and leukemia [1]. |
| In vitro | Cixutumumab（IMC-A12）（0.01-100 nM；96小时）在CHLA-9、TC-71和Rh41细胞中展示至少50%的生长抑制效果[1]。 |
| In vivo | Cixutumumab（IMC-A12）（每只大鼠1毫克，腹腔注射，每周两次，连续6周）表现出广谱抗肿瘤活性，能够抑制PPTP实验中体内固态肿瘤模型[1]的生长。 |
| Synonyms | NSC742460, IMC-A12 |
| molecular weight | N/A |
| CAS | 947687-12-9 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |